Floatz logo

TRIMETAPHAN

Obesity

Vanderbilt University Medical CenterSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

361 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Cagrilintide
Novo Nordisk A/S
Phase 3BBB
Survodutide
Boehringer Ingelheim
Phase 3BBB
Mazdutide
China National Center for Cardiovascular Diseases
Phase 4BB

View all 50 →

Same molecule, other indications

TRIMETAPHAN is also rated in:

hypertensive disorderDormant
CCC
Indicative ·
48 / 100
View asset →
pure autonomic failureDormant
CC
Indicative ·
47 / 100
View asset →
multiple system atrophyDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →